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Abstract
Background: Gastric bypass surgery is a highly effective therapy for long-term weight loss in severely obese
patients, but carries significant perioperative risks including infection, wound dehiscence, and leaks from staple
breakdown. Iron status can affect immune function and wound healing, thus may influence peri-operative
complications. Common mutations in the HFE gene, the gene responsible for the iron overload disorder hereditary
hemochromatosis, may impact iron status.
Methods: We analyzed 1064 extremely obese Caucasian individuals who underwent open and laparoscopic Roux-
n-Y gastric bypass surgery at the Geisinger Clinic. Serum iron, ferritin, transferrin, and iron binding capacity were
measured pre-operatively. All patients had intra-operative liver biopsies and were genotyped for the C282Y and
H63D mutations in the HFE gene. Associations between surgical complications and serum iron measures, HFE gene
status, and liver iron histology were determined.
Results: We found that increased serum iron and transferrin saturation were present in patients with any post-
operative complication, and that increased serum ferritin was also increased in patients with major complications.
Increased serum transferrin saturation was also associated with wound complications in open RYGB, and transferrin
saturation and ferritin with prolonged lengths of stay. The presence of 2 or more HFE mutations was associated
with overall complications as well as wound complications in open RYGB. No differences were found in
complication rates between those with stainable liver iron and those without.
Conclusion: Serum iron status and HFE genotype may be associated with complications following RYGB surgery in
the extremely obese.
Background
Obesity and metabolic syndrome have been related to
abnormalities in iron metabolism and to hepatic iron
overload [1-3]. For example, serum ferritin, a commonly
used indicator of total body iron stores, increases with
BMI [4]. Hepatic iron overload has also been implicated
in the pathogenesis of non-alcoholic steatohepatitis
(NASH), a common complication of obesity. Roux-en-Y
gastric bypass (RYGB), demonstrated to produce long-
term maintenance of weight loss in the severely obese,
also improves steatosis, necroinflammatory activity, and
h e p a t i cf i b r o s i si np a t i e n t sw i t hm o r b i do b e s i t ya n d
NASH. Although iron deficiency is a long-term compli-
cation of RYGB [5], laparoscopic adjustable gastric
banding did not normalize serum ferritin levels despite
correction of other metabolic abnormalitiess u g g e s t i n g
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sity [6]. The relationship between iron status and short-
term perioperative complications of RYGB has not yet
been studied.
Iron status is commonly determined through measure-
ment of serum iron, transferrin saturation, and ferritin
levels, and through histological assessment of liver biop-
sies [7,8]. Hepatic iron overload can be attributed to
mutations in the HFE gene [9,10], the gene responsible
for the iron overload disorder hereditary hemochroma-
tosis, that also cause increases in serum transferrin
saturation and ferritin levels. Two mutations in the HFE
gene commonly occur, C282Y and H63D [11]. The
C282Y mutation is less frequent but when homozygous
is more often associated with iron overload. The H63D
mutation is more common but far less frequently asso-
ciated with iron overload. Compound C282Y/H63D het-
erozygotes are also considered to be at risk for iron
overload.
RYGB is a relatively safe surgical procedure for most
patients but does carry perioperative risks including
infection, dehiscence, leaks from staple breakdown, and
ulcers. Iron status can affect immune function by
strengthening epithelial barriers and both cellular and
humoral immune responses [12]. With the number of
RYGB procedures increasing each year, understanding
the factors associated with these risks will be important
to decrease associated morbidity, decrease costs, and
improve outcomes. Therefore, we determined whether
t h ep r e s e n c eo fh e p a t i ci r o no v e r l o a d ,a b n o r m a li r o n
indices, or HFE gene mutations influenced the rate of
post-operative complications following RYGB.
Methods
All bariatric surgical candidates at Geisinger Medical
Center were enrolled in the Geisinger Center for Nutri-
tion and Weight Management and were prospectively
recruited into a clinical research program on obesity. A
cohort of 1064 patients who underwent either open or
laparoscopic RYGB with intraoperative wedge liver
biopsy between September 2004 to May 2008 were ana-
lyzed for this study. Approval for the research was
granted by the Institutional Review Board of the Gei-
singer Clinic and all participants provided written
informed consent. The study included only Caucasians
of European descent as judged by clinician assessment;
those of non-European descent made up only 3% of
the study population and were excluded to maintain
power in the genetic analyses. Patients undergoing other
bariatric procedures or revisional procedures were
also excluded. A comprehensive medical history and
physical examination was performed during the initial
visit. Patients then underwent a minimum of 6 months
preoperative assessment and preparation period. During
this time a comprehensive set of clinical and laboratory
measures (reference ranges) were obtained including
serum iron (males 45-160 ug/dL; females 30-160 ug/dL),
iron binding capacity (228-428 ug/dL), ferritin (males
30-400 ng/mL; females 13-150 ng/mL), transferrin
saturation (15-55%), white blood cell count (WBC: 4.0-
10.8 K/uL), red blood cell count (RBC: males 4.50-5.25
M/ul; females 3.85-5.15 M/ul), hemoglobin (males 14.0-
16.5 gm/dL; females 12.0-14.5 gm/dL), hematocrit
(HCT: males 40-47%; females 36-44.5%), mean cell
volume (MCV: males 82-99.5 fL; females 81.5-97.5 fL),
mean cell hemoglobin (MCH: 27-34 pg/cell), and mean
cell hemoglobin concentration (MCHC: 32-36 gm/dL),
platelet count (150-400 K/ul), zinc (60-130 ug/dL), and
folic acid (4.2-19.9 ng/mL). Clinical data were extracted
from the EpicCare EHR and read into SAS/STAT soft-
ware (SAS Institute Inc., Cary, NC).
Liver biopsy specimens were formalin fixed and
stained with hematoxylin and eosin for routine histol-
ogy, Masson’s trichrome for assessment of fibrosis, and
Perls’/Prussian Blue stain to determine iron status. All
specimens were read by experienced pathologists using
the criteria for NASH of Brunt [13]. DNA was prepared
as previously described [14]. Single nucleotide poly-
morphism (SNP) genotyping was performed on an
Applied Biosystems 7500 real-time PCR System (Applied
Biosystems, Foster City, CA). Assay reagents for each
SNP were obtained from Applied Biosystems (HFE
C282Y, rs1800562, C___1085595_10; HFE H63D,
rs1799945, C___1085600_10). The reaction was then
analyzed using Applied Biosystems Sequence Detection
Software. The Institutional Review Board of the Gei-
singer Clinic approved the research protocol and all par-
ticipants provided written informed consent.
Patients were followed for a 30-day period to deter-
mine length of stay and post-operative complications.
Complications [15-19] were categorized as in Table 1.
Descriptive statistics such as the calculation of means,
percentages and confidence intervals were used to
describe the study population. Chi-square tests, Fisher’s
exact tests, and Wilcoxon rank-sum tests were used to
compare abnormal iron pathology, serum levels, and
gene mutation results between those with and without
the primary outcomes (i.e. complications and extended
length of stay). Analyses compared the rate of any com-
plication, the rate of major complication, and the rate of
minor complications to the no complication group.
Wound complications were also evaluated in patients
with open RYGB. SAS version 9.1 (Cary, NC) was used
for data manipulation and statistical analysis. All tests
were two-sided, and p-values < 0.05 were considered
significant.
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The mean age of our patients was 46.5 years old of
whom 80% were females (Table 2) and all were of Cau-
casian descent. Hepatic iron staining determined by
liver biopsy obtained during RYGB surgery was noted
in 17.2% patients (n = 183), while 82.8% (n = 881) of
the patients studied had no evidence of increased liver
iron. Median serum iron parameters obtained from
blood samples obtained prior to surgery fell within the
normal range. A total of 11% of the patients studied
were either homo- or heterozygous for the C282Y
mutation and 27% were either homo- or heterozygous for
the H63D mutation (Table 2). Type 2 diabetes and
hypertension were present in over one-third of patients,
with a 1% incidence of biliary disease (Table 3). Just over
10% were on hormone replacement therapy or were
using oral contraceptives. Less than 10% were on oral
iron supplementation and most patients were non-smo-
kers and non-drinkers. Approximately two-thirds of
patients had hepatic steatosis, one-quarter had hepatic
fibrosis, and 2% manifested cirrhosis. The median com-
plete blood counts and folate and zinc levels were
normal.
Of the 1064 patients in our study, 154 of those patients
(14%) had some kind of a complication (Table 4). The
laparoscopic group had a 9% overall complication rate in
comparison to the open group which had an 18% compli-
cation rate (Chi-square p < 0.0001). There was no signifi-
cant difference in the major complication rates between
the laparoscopic (n = 29/640, 4.5%) and open (n = 18/
424, (4.2%) groups (Chi-square p = .082). Wound
infections were the primary complication in both the
open and laparoscopic groups, but the rate of both major
and minor wound complications as a percentage of com-
plications was higher in the open RYGB cohort (72%
Table 1 Major and minor complications
Major:
Death from any cause
Reoperations for any cause
Respiratory including hypoxia, hypercarbia, reintubation, or significant dyspnea
Bleeding including post-operative blood loss sufficient to require transfusion or reoperation
Wound complications requiring readmission to the hospital
Leak including leak from pouch, anastomosis, or excluded stomach
Thromboembolism including proven deep vein thrombosis or pulmonary embolus
Gastrointestinal including paralytic ileus, intestinal ischemia, intestinal obstruction or internal hernia
Acute renal failure including renal failure requiring dialysi
Other severe problems causing readmission
Minor:
Feeding intolerance including delayed discharge because foregut symptoms delayed diet progression
Cardiac including atrial fibrillation or flutter
Infection including pneumonia, sepsis, cellulitis, fever, clostridia difficile infection, or wound infection
Urinary including urinary tract infection, or urinary retention
Superficial wound complications which did not require or prolong hospitalization
Minor respiratory problems which did not require or prolong hospitalization
Stricture including gastro-jejunal anastomotic stricture
Other minor problems without readmission
Table 2 Demographics and iron parameters of study
population (N = 1064)
Demographic/Iron Parameter Result
Age (years), Mean (SD) 46.5 (11.0)
Gender
Male (%) 209 (20%)
Female (%) 855 (80%)
Weight (lbs.), Mean (SD)
Baseline 307 (62)
Surgery 293 (60)
BMI (kg/m
2), Mean (SD)
Baseline 50.2 (8.7)
Surgery 47.9 (8.3)
Hepatic iron staining 183 (17.2%)
Serum iron (ug/dL)*, Median [Q1, Q3] 62 [50, 79]
Ferritin (ng/mL)*, Median [Q1, Q3] 99 [50, 167]
Iron binding capacity (ug/dL)*, Median [Q1, Q3] 316 [287, 349]
Transferrin saturation (%)*, Median [Q1, Q3] 20 [15, 25]
HFE C282 NORMAL 950 (89%)
HFE C282Y HETEROZYGOUS 111 (10%)
HFE C282Y HOMOZYGOUS 3 (<1%)
HFE H63D NORMAL 777 (73%)
HFE H63D HETEROZYGOUS 257 (24%)
HFE H63D HOMOZYGOUS 30 (3%)
*Serum iron, ferritin, iron binding capacity, and transferring saturation were
available for n = 894, n = 900, n = 895, and n = 891 subjects, respectively.
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There were no deaths in this series.
Post-operative surgical complications were then ana-
lyzed as a function of iron staining of liver tissue obtained
during surgery and pre-operative levels of several serum
iron parameters (Table 5). There was no significant dif-
ference in any complication, major or minor, between
those patients with hepatic iron staining and those with
no evidence of increased liver iron. Patients with any
complication did have significantly higher pre-operative
median serum iron and transferrin saturation levels,
while those with major complications also had signifi-
cantly higher pre-operative median serum iron and
transferrin saturation levels, as well as higher serum fer-
ritin. Of those patients with an abnormally elevated
serum level of an iron parameter, only abnormally high
transferrin saturation levels were associated with signifi-
cantly more complications of any kind (p = 0.003) and
with minor complications (p = 0.001). Major complica-
tions were not significantly associated with abnormally
elevated levels of any of the serum iron parameters.
We then evaluated surgical complications as a func-
tion of pre-operative serum iron levels and the hepatic
iron overload genetic mutations C282Y and H63D
(Table 6). Neither the C282Y nor the H63D mutations
were significantly predictive of any complication, or
major or minor complications. However, the combina-
tion of two allele hits (heterozygous for both C282Y and
H63D or homozygous for either) did significantly pre-
dict any complication (p = .043).
Because the majority of complications in open RYGB
are wound complications, we analyzed iron status in this
subset of patients (Table 7). There was no significant dif-
ference in the patients with and without wound
Table 3 Characteristics of the study population (N =
1064)
Characteristic Result
Diabetes (%) 373 (35%)
Hypertension (%) 451 (42%)
Biliary disease (%) 15 (1%)
Contraceptive or estrogen use (%) 116 (11%)
Iron supplementation (%) 80 (8%)
Tobacco Use (known for N = 883)
Current (%) 97 (11%)
Quit (%) 332 (38%)
Never (%) 454 (51%)
Alcohol Use (known for N = 764)
Yes (%) 271 (35%)
No (%) 493 (65%)
Any steatosis on liver pathology (%) 718 (67%)
Fibrosis (%) 253 (24%)
Cirrhosis (%) 24 (2%)
Laboratory results
Complete blood counts (known for N = 1038)
WBC (K/uL), Median [Q1, Q3] 7.8 [6.5, 9.4]
RBC (M/uL), Median [Q1, Q3] 4.6 [4.3, 4.9]
Hemoglobin (gm/dL), Median [Q1, Q3] 13.7 [13.0, 14.5]
HCT (%), Median [Q1, Q3] 40.0 [37.9, 42.3]
MCV (fL), Median [Q1, Q3] 87.3 [84.3, 90.0]
MCH (pg/cell), Median [Q1, Q3] 30.0 [28.8, 31.0]
MCHC (gm/dL), Median [Q1, Q3] 34.3 [33.9, 34.7]
Platelet count (K/uL), Median [Q1, Q3] 284 [245, 331]
Folic acid (ng/dL), Median [Q1, Q3] 14.9 [10.9, 20.0]
Serum zinc (ug/L), Median [Q1, Q3] 742 [667, 819]
Table 4 Summary of 30-day complications for open and laparoscopic RYGB procedures
Total
N = 1064
Open surgery
N = 640
Laparoscopic surgery
N = 424
No complications 910 (86%) 523 (82%) 387 (91%)
Any complication (major or minor) 154 (14%) 117 (18%) 37 (9%)
Major Minor Major Minor
Type of complication* 29 88 18 19
Wound 94 12 72 2 8
Blood loss/anemia 11 7 0 4 0
Respiratory 8 2 5 0 1
Leak 7 1 0 6 0
Stricture 6 0 1 5 0
Nausea/Vomiting/Dehydration 6 1 4 0 1
Renal 5 0 3 0 2
Death 0 0 0 0 0
Other 20 7 5 1 7
*Subjects may have more than one type of complication. Hence, the total number of complications is more than the number of subjects with a complication.
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with at least 2 HFE mutations had a significantly
increased risk for wound complications after open RYGB
(p = 0.010). Patients with wound complications also
had higher pre-operative transferrin saturation levels
(p = 0.0027).
Complications can affect the post-operative length of
stay. The mean length of stay (LOS) was 2.6 days, which
was not significantly different by hepatic iron staining or
by serum iron parameters (data not shown). We also
evaluated those patients with prolonged LOS (>4 days).
Transferrin saturation and ferritin levels were higher in
patients with LOS > 4 days (Table 8). No significant dif-
ference in LOS was found based on HFE gene mutation
status (data not shown).
We then reanalyzed the data in the context of gender,
the presence of type 2 diabetes, and hypertension (data
not shown). Except for open versus laparoscopic com-
parisons, most of the results were not impacted by stra-
tification either by gender, diabetes, or hypertension,
except for a higher rate in minor complications in
females (10% vs. 5%, p < 0.035) and in any complica-
tions in non-diabetics (8% vs. 2%, p < 0.013) in patients
with the combination of two HFE allele hits (heterozy-
gous for both C282Y and H63D or homozygous for
either). Re-analysis of data for 30-day complications in
open versus laparoscopic RYGB procedures after strati-
fying for gender, the presence of type 2 diabetes and
hypertension (data not shown), revealed a statistically
higher percentage of females with abnormal serum iron
levels (3% vs. <1%, p < 0.049) and a higher percentage
of females who were homozygous for the HFE H63D
allele (8% vs. 2%, p < 0.032) for those with any compli-
cation. Iron binding capacity in males was higher (335
vs. 304, p < 0.049) in those with wound complications.
More non-diabetics with wound complications were
homozygous for the H63D allele (11% vs. 1%, p <
0.0049).
The relationship of serum iron parameters and hepatic
iron staining to HFE gene status was also determined
Table 5 Comparison of iron status with complications
COMPLICATIONS None
N = 910
Any*
N = 154
Any vs. None
p-value
Major*
N=4 7
Major vs. None
p-value
Minor*
N = 107
Minor vs. None
p-value
Hepatic Iron Staining 152 (17%) 31 (20%) 0.30
2 10 (21%) 0.41
2 21 (20%) 0.42
2
Serum iron (ug/dL)
Median [Q1, Q3] 61 [49, 77] 67 [54, 83] 0.008
1 69 [57, 83] 0.013
1 66 [52, 83] 0.097
1
Abnormal (% > 160) 3 (<1%) 2 (1%) 0.17
2 0 (0%) 0.99
2 2 (2%) 0.098
2
Ferritin (ng/mL)
Median [Q1, Q3] 99 [49, 163] 105 [62, 195] 0.093
1 120 [70, 235] 0.024
1 91 [61, 184] 0.52
1
Abnormal (% > 400) 30 (4%) 5 (4%) 0.99
2 4 (10%) 0.083
2 1 (1%) 0.24
2
Iron binding capacity (ug/dL)
Median [Q1, Q3] 316 [288, 348] 316 [284, 352] 0.91
1 313 [283, 348] 0.77
1 321 [284, 353] 0.74
1
Abnormal (% > 428) 21 (3%) 3 (2%) 0.99
2 1 (3%) 0.99
2 2 (2%) 0.99
2
Transferrin saturation (%)
Median [Q1, Q3] 19 [15, 25] 21 [17, 27] 0.017
1 24 [19, 28] 0.011
1 21 [16, 27] 0.19
1
Abnormal (% > 55) 0 (0%) 3 (2%) 0.003
2 0 (0%) NA 3 (3%) 0.0014
2
*Complications were limited to those occurring within 30-days of discharge.
1Wilcoxon rank-sum test;
2Fisher’s exact test.
Table 6 Comparison of HFE gene status with complications using Fisher’s exact test
Complications None
N = 910
Any*
N = 154
Any vs. None
p-value
Major*
N=4 7
Major vs. None
p-value
Minor*
N = 107
Minor vs. None
p-value
C282Y
Normal/Hetero, N (%) 907 (99%) 154 (100%) 0.99 47 (100%) 0.99 107 (0%) 0.99
Homo, N (%) 3 (<1%) 0 (0%) 0 (0%) 0 (0%)
H63D
Normal/Hetero, N (%) 888 (98%) 146 (95%) 0.065 44 (94%) 0.12 102 (95%) 0.19
Homo, N (%) 22 (2%) 8 (5%) 3 (6%) 5 (5%)
C282Y/H63D**
Allele dose <2 870 (96%) 141 (92%) 0.043 43 (91%) 0.27 98 (92%) 0.089
Allele dose 2+ 40 (4%) 13 (8%) 4 (9%) 9 (8%)
*Complications were limited to those occurring within 30-days of discharge.
**An allele dose of 2+ includes all patients that were Homozygous for C282Y, Homozygous for H63D, or Heterozygous for both C282Y and H63D.
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C282Y or H63D mutations by themselves, in part due
to the reduced power from small numbers of homozy-
gotes. However, increased serum iron (p < 0.0005),
transferrin saturation (p < 0.0001), and percentage with
elevated ferritin levels (p < 0.037) was found in patients
with 2 or more HFE mutations, whether C282Y or
H63D, consistent with their expected effects on iron
metabolism.
Discussion
Minimizing peri-operative complications in RYGB is
important because morbidly obese patients have signifi-
cant operative risks, many related to associated co-mor-
bidities. Iron status is a potentially important factor
influencing these co-morbidities. We found that
increased serum iron and transferrin saturation mea-
sured pre-operatively were associated with post-opera-
tive complications and that increased serum ferritin, as
well as iron and transferrin saturation, were associated
with major complications. Pre-operatively increased
serum transferrin saturation was also associated with
wound complications following open RYGB and trans-
ferrin saturation and ferritin with prolonged lengths
of stay. The presence of 2 or more HFE mutations was
associated with overall complications as well as wound
complications in open RYGB. No differences were found
in complication rates between those with stainable liver
iron and those without histological evidence of hepatic
iron overload. Stratifying by gender and diabetes also
revealed several other associations of higher iron status
in patients with complications.
The relationship between iron status and complica-
tions may be due oxidative stress. Iron is the most
abundant transition metal in the human body and is an
essential element for life [20]. It is potentially toxic
because of its ability to generate toxic free radicals and
resulting cellular injury from oxidative stress [21]. As a
protective measure, iron is sequestered in proteins, par-
ticularly ferritin and transferrin. Iron-catalyzed genera-
tion of oxidative stress has been implicated in many
clinical disorders, including wound healing and infec-
tion. In wounds there is a low pH, a partial ischemic
state, and an excess of free radicals [22]. Under these
conditions, iron may be released from storage, thereby
making it available to catalyze further tissue damage.
Our findings that serum iron and transferrin saturation
were increased in patients with complications, particu-
larly wound complications, is consistent with the avail-
ability of increased iron that could play a role in the
pathogenesis of complications. We found only a higher
level of ferritin in patients with major complications.
Ferritin is also an acute phase response protein and may
be a marker for a sub-clinical inflammatory state
Table 7 Summary of 30-day wound complications in
patients undergoing OPEN RYGB
Wound Complications None
N = 556
Any
N=8 4
Any vs.
None
p-value
Hepatic Iron Staining 109 (20%) 14 (17%) 0.66
2
Serum iron (ug/dL)*
Median [Q1, Q3] 59 [47, 75] 62 [52, 81] 0.18
1
Abnormal (% > 55) 2 (<1%) 2 (3%) 0.097
2
Ferritin (ng/mL)*
Median [Q1, Q3] 103 [55, 167] 94 [62, 184] 0.89
1
Abnormal (% > 55) 21 (4%) 2 (3%) 0.76
2
Iron binding capacity
(ug/dL)*
Median [Q1, Q3] 314 [288,
347]
323 [284,
353]
0.73
1
Abnormal (% > 55) 13 (3%) 2 (3%) 0.99
2
Transferrin saturation (%)*
Median [Q1, Q3] 19 [15, 25] 21 [16, 26] 0.33
1
Abnormal (% > 55) 0 (0%) 3 (4%) 0.0027
2
C282Y
Normal/Hetero, N
(%)
555 (99%) 84 (100%) 0.99
1
Homo, N (%) 1 (<1%) 0 (0%)
H63D
Normal/Hetero, N
(%)
543 (98%) 79 (94%) 0.074
1
Homo, N (%) 13 (2%) 5 (6%)
C282Y/H63D**
Allele dose <2 535 (96%) 75 (89%) 0.010
1
Allele dose 2+ 21 (4%) 9 (11%)
*Serum iron, ferritin, iron binding capacity, and transferring saturation were
available for n = 541, n = 546, n = 542, and n = 540 subjects, respectively.
**An allele dose of 2+ includes all that were homozygous for C282Y,
homozygous for H63D, and compound heterozygous for both C282Y and H63D.
Table 8 Comparison of iron status with length of stay
Length of stay <4 days
N = 947
4+ days
N = 117
p-value
Hepatic Iron Staining 159 (17%) 24 (21%) 0.30
2
Serum iron (ug/dL)*
Median [Q1, Q3] 61 [49, 77] 63 [52, 83] 0.062
1
Abnormal (% > 160) 5 (<1%) 0 (0%) 0.99
2
Ferritin (ng/mL)*
Median [Q1, Q3] 94 [49, 163] 118 [68, 195] 0.0093
1
Abnormal (% > 400) 33 (4%) 2 (2%) 0.42
2
Iron binding capacity (ug/dL)*
Median [Q1, Q3] 316 [287, 348] 313 [290, 352] 0.68
1
Abnormal (% > 428) 22 (3%) 2 (2%) 0.99
2
Transferrin saturation (%)*
Median [Q1, Q3] 19 [15, 25] 22 [17, 27] 0.026
1
Abnormal (% > 55) 3 (<1%) 0 (0%) 0.99
2
*Serum iron, ferritin, iron binding capacity, and transferring saturation were
available for n = 894, n = 900, n = 895, and n = 891 subjects, respectively.
1Wilcoxon rank-sum test;
2Fisher’s exact test.
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Hepatic Iron
Staining
Serum Iron (ug/dL) Ferritin (ng/mL) Iron binding capacity (ug/dL) Transferrin saturation (%)
Nw i t h
data
Iron
staining
(%)
N
with
data
Median
[Q1, Q3]
Abnormal (%
> 160)
N with
data
Median
[Q1, Q3]
Abnormal
(% > 400)
N with
data
Median
[Q1, Q3]
Abnormal
(% > 428)
N with
data
Median
[Q1, Q3]
Abnormal
(% > 55)
C282Y
Normal/Hetero
(N = 1061)
1061 182 (17%) 892 62 [50, 79] 5 (<1%) 898 99 [50, 167] 34 (4%) 893 316 [287, 349] 24 (3%) 889 20 [15, 25] 3 (<1%)
Homo (N = 3) 3 1 (33%) 2 106 [106,
106]
0 (0%) 2 306 [112,
500]
1 (50%) 2 316 [284, 349] 0 (0%) 2 34 [30, 37] 0 (0%)
p-value
A 0.43 NA 0.99 NA 0.076 NA 0.99 NA 0.99
H63D
Normal/Hetero
(N = 1034)
1034 178 (17%) 868 62 [49, 79] 5 (<1%) 872 99 [50, 167] 33 (4%) 869 316 [287, 349] 23 (3%) 865 20 [15, 25] 2 (<1%)
Homo (N = 30) 30 5 (17%) 26 63 [57, 67] 0 (0%) 28 86 [44, 171] 2 (7%) 26 316 [272, 348] 1 (4%) 26 21 [17, 24] 1 (33%)
p-value
A 0.99 0.75 0.99 0.75 0.30 0.38 0.51 0.49 0.085
C282Y/H63D*
Allele dose <2
(N = 1011)
1011 172 (17%) 847 61 [49, 78] 3 (<1%) 851 99 [50, 167] 30 (4%) 848 317 [288, 349] 23 (3%) 844 19 [15, 25] 0 (0%)
Allele dose 2 +
(N = 53)
53 11 (21%) 47 69 [59, 90] 2 (4%) 49 91 [49, 187] 5 (10%) 47 298 [272, 335] 1 (2%) 47 24 [19, 32] 3 (6%)
p-value
A 0.46 0.0005 0.024 0.98 0.037 0.0073 0.99 <.0001 0.0001
*An allele dose of 2+ includes all patients that were Homozygous for C282Y, Homozygous for H63D, or Heterozygous for both C282Y and H63D.
A = p-values are resulted from Fisher’s exact test and wilcoxon rank sum test.
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9pre-disposing to major complications in open RYGB and
not reflecting differences in iron status.
Iron may also be deleterious if present in insufficient
amounts. It is required for the hydroxylation of proline
and lysine required in collagen synthesis, thus iron defi-
ciency may collagen production and delay wound heal-
ing [23]. A reduction in oxygen carrying capacity with
iron deficiency may also affect wound healing. Iron
levels need to be in an optimal range, neither deficiency
not elevated, in order for optimum physiological
responses to surgical procedures.
Consistent with the results for serum iron parameters,
we found that patients carrying 2 or more HFE gene
mutations had a two-fold higher rate of overall compli-
cations, though each individual mutation did not reach
statistical significance. The HFE C282Y mutation has
been associated with venous leg ulceration [24] suggest-
ing that HFE genotype may affect wound complications
and healing. Patients with HFE gene mutations absorb
increased amounts of dietary iron that is characteristi-
cally reflected as an elevation of transferrin saturation
[25]. The HFE C282Y and H63D mutations cause
increased iron absorption whether in a homozygous, i.e.,
C282Y/C282Y or H62D/H62D, or compound heterozy-
gous configuration, i.e., C282Y/H63D. However, the bio-
chemical expression of HFE mutations is variable. In a
study of over 200 C282Y homozygotes, a total of 28% of
male C282Y homozygotes had evidence of iron-over-
load-related disease [26]. In contrast, the prevalence of
iron-overload-related disease was only 1% in female
C282Y homozygotes, which may be due to a lower iron
burden and/or other modifying effects. In our popula-
tion, about 80% of the patients were female, thus the
clinical expression of mutations may be under-
represented.
Despite the association of complications with serum
iron indices, the presence of stainable iron in the liver
was not associated with post-operative RYGB complica-
tions. The liver serves as a major storage depot for total
body iron. Total body iron stores are generally propor-
tional to serum ferritin, although the correlation is not
very strong [27]. In the absence of HFE mutations, the
levels of serum iron and transferrin saturation may not
be indicative of increased iron absorption and increased
iron stores, thus stainable liver iron may not be
expected to predict the same outcomes as serum iron
and transferrin saturation.
A higher rate of wound complications, defined as
superficial and deep surgical site infections and dehis-
cence, was found in patients undergoing open RYGB
versus those who had laparoscopic RYGB. This is simi-
lar to reports in the literature of wound problems occur-
ring in about 10-20% of patients following open RYGB
[19,28]. A majority of the complications in RYGB were
considered minor, whereas in laparoscopic RYGB
approximately equal numbers of major and minor com-
plications were seen.
Obesity is a known risk factor for several types of
complications in other surgeries. For example, overall
postoperative complications have been associated with
BMI in patients with non-perforated appendicitis [29].
Increased BMI has also been associated with increased
wound complications in both minimally invasive and
open rectal surgery [30,31]. Percent body fat calculated
by bioelectrical impedance analysis has been associated
with a 5-fold increased risk of surgical site infections
after elective surgery [32]. However, BMI may not affect
complication rates for all types of operations. Although
total laparoscopic hysterectomy for obese patients
required significantly longer to complete and was asso-
ciated with a higher risk of significant blood loss, major
and minor complications, hospital readmission, and
reoperation were not different [33].
There are several limitations to our study. The only
operation studied was RYGB. The findings do not
apply to other types of bariatric surgeries, such as the
laparoscopic band procedure. The relative number of
men enrolled in the study was much lower than the
number of women, so limited statistical power exists to
determine whether the associations found for female
patients are truly not present in males. Follow-up stu-
dies with larger numbers of male patients will be
required. The numbers of C282Y and H63D homozy-
gotes was also relatively low and thus not sufficiently
powered to determine whether these genotypes were
associated with differences in complication rates. A
much larger sample size will be required given the low
rates of these mutations. Our population also consisted
of only Caucasian patients. Whether iron status in
patients of other races/ethnicities is associated with
post-RYGB complications will need to be determined
in other studies. We also did not address independent
effects of other variables on complications, such as
blood glucose levels and BMI.
Conclusion
In summary, serum markers for iron and HFE gene
mutations were associated with complications after
RYGB. The serum iron indices and HFE gene mutations
may be markers for patient at risk for complications and
wound healing problems. The use of genetic markers to
identify patients at risk for surgical outcomes, i.e., “surgi-
cogenomics” [14] is analogous to using genetic variants
to predict response to medications, i.e., pharmacoge-
nomics. The precise role of iron and HFE mutations in
the pathophysiology of post-operative complications
in morbidly obese patients following RYGB needs to be
further defined.
Gerhard et al. Patient Safety in Surgery 2011, 5:1
http://www.pssjournal.com/content/5/1/1
Page 8 of 9Acknowledgements
We thank SAGES and Covidien for providing funding through research
grants. We also acknowledge support from Geisinger Clinic, the Weis Center
for Research, and the Geisinger Obesity Research Institute.
Author details
1Weis Center for Research, Geisinger Clinic, 100 North Academy Avenue,
Danville, PA 17822, USA.
2Dept of Surgery, Geisinger Medical Center, 100
North Academy Avenue, Danville, PA 17822, USA.
3Geisinger Obesity
Research Institute, Geisinger Clinic, 100 North Academy Avenue, Danville, PA
17822, USA.
4Dept of Surgery, St. Francis Medical Center, Trenton, NJ 08629,
USA.
Authors’ contributions
GSG and ATP were responsible for developing the idea of this study. GSG,
ATP, CDS, and PB contributed to the study design. RC and ATP were
involved in the records review and data acquisition. CGW conducted the
statistical analyses. GSG performed the literature review and drafting of the
manuscript. All authors were involved in reviewing and editing the
manuscript. All authors read and have approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 November 2010 Accepted: 10 January 2011
Published: 10 January 2011
References
1. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc’h A, Deugnier Y:
Histologic features of the liver in insulin resistance-associated iron
overload. A study of 139 patients. Am J Clin Pathol 2001, 116(2):263-70.
2. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le
Gall JY, Brissot P, David V, Deugnier Y: Insulin resistance-associated
hepatic iron overload. Gastroenterology 1999, 117(5):1155-63.
3. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y: A new
syndrome of liver iron overload with normal transferrin saturation.
Lancet 1997, 349(9045):95-7.
4. Ausk KJ, Ioannou GN: Is obesity associated with anemia of chronic
disease? A population-based study. Obesity (Silver Spring) 2008,
16(10):2356-61.
5. von Drygalski A, Andris DA: Anemia after bariatric surgery: more than just
iron deficiency. Nutr Clin Pract 2009, 24(2):217-26.
6. Gastaldelli A, Perego L, Paganelli M, Sesti G, Hribal M, Chavez AO,
Defronzo RA, Pontiroli A, Folli F: Elevated concentrations of liver enzymes
and ferritin identify a new phenotype of insulin resistance: effect of
weight loss after gastric banding. Obes Surg 2009, 19(1):80-6.
7. Brunt EM: Pathology of hepatic iron overload. Semin Liver Dis 2005,
25(4):392-401.
8. Turlin B, Deugnier Y: Evaluation and interpretation of iron in the liver.
Semin Diagn Pathol 1998, 15(4):237-45.
9. Brunt EM, Olynyk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR:
Histological evaluation of iron in liver biopsies: relationship to HFE
mutations. Am J Gastroenterol 2000, 95(7):1788-93.
10. Chorney MJ, Yoshida Y, Meyer PN, Yoshida M, Gerhard GS: The enigmatic
role of the hemochromatosis protein (HFE) in iron absorption. Trends Mol
Med 2003, 9(3):118-25.
11. Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, Pockros P,
Kosty M, Venditti CP, Phatak PD, Seese NK, Chorney KA, Ten Elshof AE,
Gerhard GS, Chorney M: Mutation analysis in hereditary
hemochromatosis. Blood Cells Mol Dis 1996, 22(2):187-94, discussion 194a-
194b.
12. Maggini S, Wintergerst ES, Beveridge S, Hornig DH: Selected vitamins and
trace elements support immune function by strengthening epithelial
barriers and cellular and humoral immune responses. Br J Nutr 2007,
98(Suppl 1):S29-35.
13. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR:
Nonalcoholic steatohepatitis: a proposal for grading and staging the
histological lesions. Am J Gastroenterol 1999, 94(9):2467-74.
14. Chu X, Erdman R, Susek M, Gerst H, Derr K, Al-Agha M, Wood GC,
Hartman C, Yeager S, Blosky MA, Krum W, Stewart WF, Carey D, Benotti P,
Still CD, Gerhard GS: Association of morbid obesity with FTO and INSIG2
allelic variants. Arch Surg 2008, 143(3):235-40, discussion 241.
15. Benotti PN, Still CD, Wood GC, Akmal Y, King H, El Arousy H, Dancea H,
Gerhard GS, Petrick A, Strodel W: Preoperative weight loss before bariatric
surgery. Archives of surgery (Chicago, Ill 2009, 144(12):1150-5.
16. Still CD, Benotti P, Wood GC, Gerhard GS, Petrick A, Reed M, Strodel W:
Outcomes of preoperative weight loss in high-risk patients undergoing
gastric bypass surgery. Arch Surg 2007, 142(10):994-8, discussion 999.
17. Derzie AJ, Silvestri F, Liriano E, Benotti P: Wound closure technique and
acute wound complications in gastric surgery for morbid obesity: a
prospective randomized trial. J Am Coll Surg 2000, 191(3):238-43.
18. Jones KB Jr, Afram JD, Benotti PN, Capella RF, Cooper CG, Flanagan L,
Hendrick S, Howell LM, Jaroch MT, Kole K, Lirio OC, Sapala JA,
Schuhknecht MP, Shapiro RP, Sweet WA, Wood MH: Open versus
laparoscopic Roux-en-Y gastric bypass: a comparative study of over
25,000 open cases and the major laparoscopic bariatric reported series.
Obes Surg 2006, 16(6):721-7.
19. Benotti PN, Wood GC, Rodriguez H, Carnevale N, Liriano E: Perioperative
outcomes and risk factors in gastric surgery for morbid obesity: a 9-year
experience. Surgery 2006, 139(3):340-6.
20. Aisen P, Enns C, Wessling-Resnick M: Chemistry and biology of eukaryotic
iron metabolism. Int J Biochem Cell Biol 2001, 33(10):940-59.
21. Meneghini R: Iron homeostasis, oxidative stress, and DNA damage. Free
Radic Biol Med 1997, 23(5):783-92.
22. Yeoh-Ellerton S, Stacey MC: Iron and 8-isoprostane levels in acute and
chronic wounds. J Invest Dermatol 2003, 121(4):918-25.
23. Williams JZ, Barbul A: Nutrition and wound healing. The Surgical clinics of
North America 2003, 83(3):571-96.
24. Zamboni P, Tognazzo S, Izzo M, Pancaldi F, Scapoli GL, Liboni A,
Gemmati D: Hemochromatosis C282Y gene mutation increases the risk
of venous leg ulceration. J Vasc Surg 2005, 42(2):309-14.
25. Alexander J, Kowdley KV: HFE-associated hereditary hemochromatosis.
Genet Med 2009, 11(5):307-13.
26. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ,
McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC,
Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM: Iron-
overload-related disease in HFE hereditary hemochromatosis. N Engl J
Med 2008, 358(3):221-30.
27. Beutler E, Felitti V, Ho NJ, Gelbart T: Relationship of body iron stores to
levels of serum ferritin, serum iron, unsaturated iron binding capacity
and transferrin saturation in patients with iron storage disease. Acta
Haematol 2002, 107(3):145-9.
28. Topaloglu S, Avsar FM, Ozel H, Babacan M, Berkem H, Yildiz Y, Hengirmen S:
Comparison of bariatric and non-bariatric elective operations in
morbidly obese patients on the basis of wound infection. Obes Surg
2005, 15(9):1271-6.
29. Sadr Azodi O, Lindstrom D, Adami J, Bellocco R, Linder S, Wladis A: Impact
of body mass index and tobacco smoking on outcome after open
appendicectomy. The British journal of surgery 2008, 95(6):751-7.
30. Balentine CJ, Robinson CN, Marshall CR, Wilks J, Buitrago W, Haderxhanaj K,
Sansgiry S, Petersen NJ, Bansal V, Albo D, Berger DH: Waist circumference
predicts increased complications in rectal cancer surgery. Journal of
gastrointestinal surgery 2010, 14(11):1669-79.
31. Balentine CJ, Wilks J, Robinson C, Marshall C, Anaya D, Albo D, Berger DH:
Obesity increases wound complications in rectal cancer surgery. The
Journal of surgical research 2010, 163(1):35-9.
32. Waisbren E, Rosen H, Bader AM, Lipsitz SR, Rogers SO, Eriksson E: Percent
body fat and prediction of surgical site infection. Journal of the American
College of Surgeons 2010, 210(4):381-9.
33. Heinberg EM, Crawford BL, Weitzen SH, Bonilla DJ: Total laparoscopic
hysterectomy in obese versus nonobese patients. Obstetrics and
gynecology 2004, 103(4):674-80.
doi:10.1186/1754-9493-5-1
Cite this article as: Gerhard et al.: The influence of iron status and
genetic polymorphisms in the HFE gene on the risk for postoperative
complications after bariatric surgery: a prospective cohort study in
1,064 patients. Patient Safety in Surgery 2011 5:1.
Gerhard et al. Patient Safety in Surgery 2011, 5:1
http://www.pssjournal.com/content/5/1/1
Page 9 of 9